Advanced Filters
noise

sarcoma Clinical Trials

A listing of sarcoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 435 clinical trials

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.

20 - 80 years of age All Phase 2
B BERTUCCI François

CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

This is a prospective observational biomarker study including patients with non-metastatic, soft-tissue sarcomas (STS) for whom neoadjuvant chemotherapy is considered as the best option by the multidisciplinary sarcoma team of one of the participating centers.

18 years of age All Phase N/A
C Cihan Gani, MD

Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

"Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcoma" is a prospective study with additional translational research using preoperative and postoperative tissue, blood sampling and advanced imaging.

18 years of age All Phase N/A
Y Yong Yang, Doctor

The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities

For localized soft tissue sarcomas (STS) of the extremities, limb-sparing or conservative surgery with perioperative radiotherapy (RT) is the standard of care. However, several challenges persist. Notably, there are exceedingly high rates of distant metastatic recurrence even after surgical resection and RT, and conventional fractionated radiotherapy has a prolonged duration …

18 - 75 years of age All Phase 2

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

18 years of age All Phase 1/2

QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period. Subjects will receive QL1706 5mg/kg iv every 3 weeks until disease progression or intolerance. Efficacy should be evaluated and safety will …

18 - 75 years of age All Phase 2
S Svetlana Kulyova, MD, PhD

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Data from 40 patients are planned to be included in the study to randomize approximately 10 patients. This study involves patients with advanced/metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy, advanced/metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy and advanced/metastatic GD2-positive osteosarcoma after progression on …

- 18 years of age All Phase 3
L Lauren (Taylor) Michael

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.

18 years of age All Phase 2
L Li Yu

Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma

Soft tissue sarcoma (STS) is a kind of solid tumor with high heterogeneity. There is no standard second-line treatment plan for patients who have failed first-line treatment. NY-ESO-1, a cancer testis antigen, is highly expressed in soft tissue tumors and is an ideal therapeutic target. Investigators aim to testify the …

18 - 70 years of age All Phase N/A
J Jean-Emmanuel KURTZ, MD, PhD

Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

The primary objective of this trial is to investigate whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/- radiotherapy) improves the outcome of high-risk CINSARC patients with …

18 years of age All Phase 3

Simplify language using AI